An insulin pump that delivers the wrong dose can support two separate categories of damages: economic damages, meaning the objectively verifiable money you lost, and non-economic damages, meaning the human harm that has no receipt. In a dosing-error injury, that usually means emergency and hospital bills, lost wages and lost earning capacity on the economic side, and pain, mental suffering, emotional distress and loss of consortium on the non-economic side.
The split matters for more than vocabulary. California's damages statute, which many states echo in substance, defines each category explicitly and then treats them differently when more than one defendant is at fault. Understanding which of your losses falls where tells you what is provable with documents, what depends on testimony, and which part of a verdict is actually collectible.
Table of Contents
- What counts as economic damages after a dosing error
- Which non-economic damages apply
- Why the two categories are not equally collectible
- The dosing errors regulators have already documented
- The preemption question — and why it rarely blocks today's pumps
- Frequently Asked Questions
What counts as economic damages after a dosing error
Economic damages are losses with a number attached. California Civil Code § 1431.2(b)(1) defines them as objectively verifiable monetary losses and names the specific items: medical expenses, loss of earnings, burial costs, loss of use of property, costs of repair or replacement, loss of employment, and loss of business or employment opportunities. In an insulin over-delivery case, the medical-expense component is usually anchored by a single severe hypoglycemic event — dangerously low blood sugar requiring hospital treatment. A 2025 claims-based study of U.S.
type 1 diabetes patients, published in PubMed Central, put the average cost of one hospital-treated severe hypoglycemic event at $9,765 in 2022 dollars, with inpatient hospitalization the largest annual driver at $22,981 per patient per year. Under-delivery values differently, because the documented outcome is diabetic ketoacidosis — a life-threatening buildup of blood acids when insulin runs short. A nationwide analysis in *Diabetes Care* found inflation-adjusted mean hospital charges per DKA admission rose from $18,987 in 2003 to $26,566 in 2014. These figures are averages, not promises about your bill, but they show why a single admission can carry a five-figure economic claim before lost wages are counted.
Which non-economic damages apply
Non-economic damages cover the subjective losses. The same statute lists them: pain, suffering, inconvenience, mental suffering, emotional distress, loss of society and companionship, loss of consortium, injury to reputation and humiliation. Several of those map unusually well onto a pump failure.
A person who survives a 10-to-100-fold insulin overdose often develops lasting fear of the device they still depend on — that is mental suffering and emotional distress, not a medical bill. Severe hypoglycemia can also cause seizures or loss of consciousness, and the recovery period supports pain and inconvenience claims. Where a spouse took over care or lost the relationship they had, loss of consortium is a separate claim belonging to that spouse. Non-economic damages are proved differently, which is why documentation habits matter from the first week:.
- A dated symptom and glucose log, kept contemporaneously rather than reconstructed later
- Pump and continuous-glucose-monitor data exports showing the delivery event and the resulting excursion
- Mental-health treatment records, if you sought care for device anxiety or post-event distress
- Statements from family or coworkers describing before-and-after function
- Records of activities, work duties or travel you gave up
Why the two categories are not equally collectible
This is the part most readers do not expect. Under Cal. Civ. Code § 1431.2(a), liability for non-economic damages is several only — each defendant pays solely its own percentage of fault — while economic damages remain joint and several.
Play that out in a real case structure. Suppose a suit names the pump maker, the prescribing clinic and a pharmacy, and a jury assigns the manufacturer 60% of fault. The full economic award is collectible from any one solvent defendant, so bills and wage loss can be recovered even if the clinic is uninsured or gone. The non-economic award splits by percentage, and the 40% assigned to the other two is only as good as their ability to pay. The practical consequence: thorough documentation of economic loss protects the recoverable core of a claim, while the non-economic portion depends on both the verdict and which defendants are financially real.
The dosing errors regulators have already documented
Two recall actions show the failure modes courts have seen. FDA's Class I recall of the Omnipod 5 Android app, described in the agency's recall notice, documented that entering a bolus under 1 unit without a leading zero — ".2" instead of "0.2" — made software versions 1.1 through 1.2.3 drop the decimal and deliver 10 to 100 times the intended dose. Insulet fixed it with app version 1.2.4 on December 7, 2023, and no deaths were reported. The second is mechanical.
Medtronic began recalling MiniMed 600 series pumps with a clear retainer ring on November 21, 2019, because a damaged or missing ring lets the reservoir seat improperly and causes over- or under-delivery; the FDA device recall record notes that in October 2021 the company expanded the action to proactively replace every clear-ring pump with a black-ring version free of charge. Notice evidence sits on top of that. FDA's December 9, 2021 warning letter to Medtronic states the firm received over 74,000 retainer-ring complaints between June 2016 and November 20, 2019, more than 57,000 of which were reported to FDA as medical device reports. Complaint volume of that size is what notice-based claims and punitive damages requests turn on, because it speaks to what the manufacturer knew before the recall.
The preemption question — and why it rarely blocks today's pumps
The historical obstacle to pump damages claims is federal preemption. In *Riegel v. Medtronic, Inc.*, 552 U.S. 312 (2008), the Supreme Court held that 21 U.S.C. § 360k(a) bars state common-law claims challenging the safety or effectiveness of a Class III device that went through FDA premarket approval, because PMA imposes federal "requirements." That reasoning wiped out most design and warning damages against PMA devices.
Current insulin pumps generally sit outside it. FDA's De Novo order DEN180058 classified the "alternate controller enabled infusion pump" into Class II under 21 CFR 880.5730, and the Omnipod 5 ACE Pump (K203768), Tandem Mobi (K223213), iLet ACE Pump (K223846) and MiniMed 780G (K251032) all cleared by 510(k) under product code QFG rather than PMA. Because *Riegel* turns on premarket approval, its bar is generally unavailable to the makers of those devices. That is a regulatory-pathway question, not a guess — the clearance number tells you which route a device took. Before assuming a claim is dead, check whether the specific model and software version were cleared by 510(k) or approved by PMA, and whether the alleged defect is in the pump, a companion app, or a disposable component with its own clearance.
Frequently Asked Questions
Can I claim damages if the overdose did not require hospitalization?
Yes, but the economic component shrinks to what you can document — an urgent-care visit, missed shifts, replacement supplies. The non-economic claim still exists, and it carries proportionally more weight when medical bills are small.
Does a free replacement pump affect my claim?
A manufacturer replacing a device at no charge, as Medtronic did for clear-ring pumps in October 2021, addresses the product. It does not compensate the injury, the hospital stay, or the lost income already incurred.
Are punitive damages a separate category?
Yes. Punitive damages are neither economic nor non-economic; they punish conduct rather than replace a loss, and they depend on evidence of what the manufacturer knew. FDA's figure of over 74,000 complaints before the 2019 recall is the kind of record such a request is built on.
You Might Also Like
- A Surgical Robot Malfunction During a Procedure: Which Economic and Non-Economic Damages Could Be Available?
- A Spinal Cord Stimulator Causing Unexpected Nerve Injury: Which Economic and Non-Economic Damages Could Be Available?
- An Insulin Pump Delivering an Incorrect Dose: What Evidence Could Prove—or Defeat—Liability?